Your browser is no longer supported. Please, upgrade your browser.
SNY Sanofi daily Stock Chart
Index- P/E22.56 EPS (ttm)2.20 Insider Own16.40% Shs Outstand2.55B Perf Week0.04%
Market Cap126.09B Forward P/E14.27 EPS next Y3.47 Insider Trans0.00% Shs Float2.22B Perf Month-0.88%
Income5.63B PEG2.93 EPS next Q0.96 Inst Own10.10% Short Float0.09% Perf Quarter3.77%
Sales43.02B P/S2.93 EPS this Y1.40% Inst Trans0.17% Short Ratio2.07 Perf Half Y7.86%
Book/sh27.09 P/B1.83 EPS next Y4.52% ROA- Target Price55.00 Perf Year30.05%
Cash/sh- P/C- EPS next 5Y7.70% ROE- 52W Range36.81 - 50.65 Perf YTD22.43%
Dividend1.64 P/FCF- EPS past 5Y-4.60% ROI6.20% 52W High-1.86% Beta0.88
Dividend %3.31% Quick Ratio1.20 Sales past 5Y-0.20% Gross Margin68.60% 52W Low35.04% ATR0.48
Employees106859 Current Ratio1.60 Sales Q/Q9.80% Oper. Margin- RSI (14)51.67 Volatility0.77% 0.77%
OptionableYes Debt/Eq0.32 EPS Q/Q20.70% Profit Margin- Rel Volume5.37 Prev Close49.51
ShortableYes LT Debt/Eq0.26 EarningsNov 02 BMO Payout- Avg Volume997.43K Price49.71
Recom1.70 SMA20-0.28% SMA501.10% SMA2006.74% Volume2,939,973 Change0.40%
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-20-17 02:39PM  Sanofi Stock: Performance in 3Q17 Market Realist
Oct-19-17 09:00AM  Zacks Industry Outlook Highlights: Acorda Therapeutics, BioMarin Pharmaceutical, Valeant Pharmaceuticals International, Teva Pharmaceuticals and Sanofi Zacks
Oct-17-17 12:58PM  Regeneron-Sanofi drug succeeds mid-stage study Reuters
10:48AM  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study Zacks
09:08AM  Sanofis Consumer Healthcare Expected to Be Long-Term Driver Market Realist
Oct-16-17 06:16PM  UPDATE 1-Regeneron-Sanofi drug succeeds mid-stage study Reuters
10:40AM  Vaccines Business Expected to Boost Sanofis Revenues in 2017 Market Realist
09:19AM  Aimmune teams with Regeneron, Sanofi on peanut allergy drug Reuters
09:10AM  Sanofis Kevzara Could Be Solid Addition to Rheumatoid Arthritis Market Realist
08:17AM  Regeneron-Sanofi throat infection drug succeeds key study Reuters
08:00AM  Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis PR Newswire
07:49AM  Regeneron Advances Science To Attack Arthritis, Eye Disease, More Investor's Business Daily
07:42AM  Dupixent May Be Strong Growth Driver for Sanofi in the Future Market Realist
Oct-15-17 05:00PM  Flexion's Latest FDA Approval Reignites Takeover Chatter
Oct-13-17 06:06PM  Specialty Segment Drives Sanofis Revenue Growth in 2017 Market Realist
04:15PM  Sanofi and Its Peers: Analysts Recommendations in October Market Realist
09:32AM  Big Pharma Killed The Cancer Drug He Invented. He Raised $22 Million To Revive It Forbes
01:15AM  A New FDA Approval Sends Small Cap Flexion Soaring Motley Fool
Oct-12-17 01:03AM  Sanofi invests 170 million in new vaccine production facility in France GlobeNewswire
Oct-11-17 05:58PM  Dow's Merck Bails On Cholesterol Drug, Prodding Shares Down Investor's Business Daily
08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
08:00AM  Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis PR Newswire
Oct-10-17 04:57PM  This Biotech Hit Record High; Could Undercut Regeneron In Eczema Investor's Business Daily
Oct-09-17 09:25AM  Emergent BioSolutions Acquires Sanofi's Smallpox Vaccine Unit Zacks
Oct-08-17 09:00AM  3 High-Yield Healthcare Stocks Motley Fool
Oct-06-17 05:37PM  Why Regeneron's Patent Win Is Worse For Amgen Than You Think Investor's Business Daily
03:45PM  Top Research Reports for HSBC, UPS & General Motors Zacks
09:00AM  Regeneron and Sanofi Get Favorable Ruling Against Amgen Zacks
Oct-05-17 04:28PM  At least six funds interested in Sanofi European generic drugs unit - Le Figaro Reuters
01:51PM  [$$] Appeals Court Rules Against Amgen in Patent Case The Wall Street Journal
01:14PM  U.S. court reverses ban on sale of Regeneron, Sanofi cholesterol drug Reuters
12:30PM  Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab) PR Newswire
10:30AM  Why Regeneron Pharmaceuticals Dropped 11.3% in September Motley Fool
Oct-03-17 03:30PM  3 High-Yield International Stocks Motley Fool
Oct-02-17 09:10AM  Sanofi appoints Oelrich as executive VP at Diabetes & Cardiovascular arm Reuters
07:05AM  Ex-Genzyme head Meeker to lead Flagship drug startup KSQ American City Business Journals
Sep-29-17 09:13AM  Keryx Focuses on Kidney Drug Auryxia Despite Generic Threat Zacks
Sep-28-17 09:23AM  Sanofi Rides on Genzyme & Vaccines Unit, Diabetes Sales Weak Zacks
01:02AM  Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union GlobeNewswire
01:01AM  EU approves Sanofi and Regeneron's dupilumab in eczema Reuters
01:00AM  Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union PR Newswire
Sep-26-17 01:59PM  Pregnant women still unaware of epilepsy drug risks - EMA hearing Reuters
07:18AM  5 Numbers That Should Get MannKind Investors Excited Motley Fool
Sep-24-17 10:46AM  12 Flu Season Facts You Need to Know Motley Fool
Sep-23-17 10:49AM  Why Novavax, Inc. Could Be a Gold Mine for Growth Investors Motley Fool
10:34AM  3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher? Motley Fool
Sep-21-17 11:01AM  Alnylam/Sanofi's RNAi Drug Meets Endpoint in Study, Stock Up Zacks
09:30AM  Is Sanofi (SNY) a Great Stock for Value Investors? Zacks
Sep-20-17 04:07PM  Alnylam Rockets On Strong Rare-Disease Drug Data; Ionis Tanks Investor's Business Daily
02:01PM  Sanofi and NIH researchers develop "three-in-one" antibodies as a potential breakthrough intervention for HIV/AIDS PR Newswire
02:01PM  Alnylam Notches a Game-Changing RNAi Win Motley Fool
01:14PM  Alnylam Pharmaceuticals, Inc. (ALNY) Stock Soars on Drug Breakthrough InvestorPlace
07:39AM  UPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment MarketWatch
07:00AM  Sanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy GlobeNewswire
07:00AM  Alnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy Business Wire
06:32AM  Why Exelixis Wouldn't Be a Warren Buffett Stock Motley Fool
Sep-19-17 07:20AM  Yahoo Finance Live: Market Movers - Sep 19th, 2017 Yahoo Finance Video
Sep-18-17 07:30PM  5 Top Marijuana Stocks For 2017
05:06PM  Could Mylan See a Rise in Net Profit Margins in 2017? Market Realist
07:37AM  Kevzara May Emerge as a Prominent Rheumatoid Arthritis Drug in 2017 Market Realist
Sep-16-17 02:17AM  Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis GlobeNewswire
02:15AM  Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis PR Newswire
Sep-15-17 10:38AM  Label Expansion in Asthma Indication May Boost Dupixents Sales Market Realist
09:10AM  Regulatory Approval in Asthma Indication May Boost Dupixents Sales Market Realist
07:38AM  Dupixent Expected to Become a Leading Therapy for Atopic Dermatitis Market Realist
Sep-14-17 12:32PM  Why Lexicon Pharmaceuticals Is Down 11% Today Motley Fool
07:00AM  Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice PR Newswire
Sep-12-17 01:26PM  Sanofi indicates dupilumab could be used to treat nasal polyps Reuters
07:01AM  Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL PR Newswire
06:48AM  5 Things Regeneron's CEO Said as the Biotech Stock Sank Motley Fool
Sep-11-17 02:15PM  Regeneron/Sanofi's Dupixent Asthma Study Meets Endpoints Zacks
01:08PM  Regeneron, Sanofi asthma drug data fails to excite investors Reuters
07:25AM  Featured Company News - Regeneron Pharma and Sanofi's Cemiplimab Receives Breakthrough Therapy Designation from US FDA ACCESSWIRE
01:14AM  Sanofi and Regeneron announce positive dupilumab topline results Reuters
01:00AM  Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma PR Newswire
Sep-08-17 05:42PM  Regeneron's Cemiplimab Gains Breakthrough Therapy Status Zacks
02:59AM  Sanofi says Cemiplimab skin cancer treatment gets FDA "Breakthrough Designation" Reuters
01:00AM  Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma PR Newswire
Sep-07-17 10:52AM  Why Regeneron Is Getting Smoked
09:49AM  [$$] Sanofi Stops Work on Two Zika Vaccines The Wall Street Journal
08:50AM  Sanofi Has Good Potential Upside
Sep-04-17 09:51AM  Why Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report? Zacks
Sep-01-17 09:54AM  The Pullback In Sanofi Is A Buying Opportunity, Says Argus Benzinga
Aug-30-17 07:20AM  Corporate News Blog - Sanofi Completes Acquisition of Vaccines Biotechnology Company, Protein Sciences ACCESSWIRE
Aug-29-17 08:03AM  3 Healthcare Stocks to Buy With Dividends Yielding More Than 3% Motley Fool
Aug-26-17 03:20PM  3 International Stocks for Retirees Motley Fool
Aug-25-17 09:07AM  Januvia and Janument: An Update on Mercks Diabetes Franchise after 2Q17 Market Realist
08:00AM  Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017 PR Newswire
07:37AM  How Mercks Vaccines Business Is Positioned after 2Q17 Market Realist
Aug-24-17 11:53AM  Can Sanofi (SNY) Sustain the Solid 1H Momentum in 2H17? Zacks
09:51AM  The Zacks Analyst Blog Highlights: Duke Energy, Stryker, Sanofi, PPL Corp and Viacom Zacks
Aug-23-17 03:50PM  Top Stock Reports for Duke Energy, Stryker & Sanofi Zacks
Aug-22-17 04:04PM  Top 10 Dividend-Paying Stocks Worldwide Forbes
03:20PM  What's the Most Important Drug in Regeneron Pharmaceuticals' Pipeline? Motley Fool
09:07AM  Mylan's Stock Is No Longer A Buy According To Analysts At Argus Benzinga
Aug-21-17 05:59PM  One of the 33 Great Minds of Investing
09:31AM  Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why Zacks
Aug-18-17 10:37AM  A Look at Sanofi Pasteurs Performance in 2Q17 Market Realist
09:07AM  Sanofis General Medicines and Consumer Healthcare in 2Q17 Market Realist
07:37AM  Performance of Sanofis Established Products in 2Q17 Market Realist
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerAug 25Buy481.3672,37834,840,13323,880,537Aug 29 05:00 PM
Sanofi10% OwnerAug 24Buy482.04105,82051,009,57223,808,159Aug 25 05:00 PM
Sanofi10% OwnerAug 23Buy478.9860,59529,024,05023,702,339Aug 25 05:00 PM
Sanofi10% OwnerJun 02Buy478.17136,05065,055,55823,641,744Jun 06 05:00 PM
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM